New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma.

Takafumi SaitoKent KanaoKazuhiro MatsumotoKeishiro FukumotoDaisuke IgarashiTakayuki TakahashiGo KanekoSuguru ShirotakeKoshiro NishimotoRyuichi MizunoMasaru IshidaSatoshi HaraMototsugu OyaMasafumi Oyama

Published in: BJUI compass (2023)

Patients with cT2 and ypT2 stage have a relatively low risk of recurrence and thus have a lower need for adjuvant nivolumab, particularly those with ypT2.

Keyphrases

early stage
computed tomography
skeletal muscle
image quality
dual energy
magnetic resonance imaging
free survival